for chronic asthma, 396–397
for COPD, 420t, 422
for rhinitis, 442
Fluticasone furoate (Flonase Sensimist), 441t
for allergic rhinitis, 442
for chronic asthma, 396
Fluticasone propionate (Dymista), 441t
for allergic rhinitis, 442
Fluvastatin, 46t, 55, 110t, 116, 117t, 120t
Fluvoxamine (Luvox), 1027t, 1738t, 1748
for depression, 2245
for depressive disorders, 1820t
for diabetes, 2226t
dosage, 1758
drug interaction with smoking, 1906t
for OCD, 1760
for PTSD, 1754
Fluvoxamine CR, for SAD, 1752
Fluzone High-Dose, 1361
Folate
alcohol withdrawal, 1896
for anemia, 1936
Folic acid, 958, 961
and pregnancy, 968, 969, 979
recommended daily allowance (RDA), 969
and women, 969
Fomepizole, 562
Fondaparinux, 189, 252
for ACS, 241t
for DVT, 187
in patients with HIT, 657
UFH and LMWH and, 177–178, 177t
Formaldehyde, 822t
Formoterol
for COPD, 421, 421t, 422
for EIA, 400
Fortaz (see Ceftazidime)
Fosamprenavir (FPV), 128, 914t
for HIV, 1579t
Fosaprepitant (Emend), 472t
Foscarnet (Foscavir), 742, 1613, 1649t, 1651
adjunctive therapy, 1608t
adjusted dosage, 1610t
advantages, 1608t
adverse effects of, 1334t, 1608t, 1612, 1647t
CrCl, 1610t
disadvantages, 1608t
dosing regimens, 1608t, 1612
for herpes labialis, 1651
important drug interactions, 1608t
intravitreal administration, 1613
monitoring requirement, 1609t
normal dosage, 1610t
precautions and contraindications, 1609t
to prevent nephrotoxicity, 1612
Foscavir (see Foscarnet), 1649t
Fosfomycin, for UTI, 1489, 1489t, 1491
Fosinopril, 281, 281t, 2223
in hypertension, 153t
Fosphenytoin, 55, 942t, 1288
in SE, 1299
for seizures, 1284t
FPV (see Fosamprenavir (FPV))
FreAmine HBC, 794t
FreAmine III, 794t
Frovatriptan, 1237, 1238t, 1239
FTC (see Emtricitabine (FTC))
Furazolidone, for giardiasis, 1707
Furosemide, 543–544, 546, 580, 589–590, 1991–1993, 2223
doses of, 277
for HF, 276–277
for hypercalcemia, 589t
for hypertension, 148
for nephrotic edema, 574
for PDA, 2179, 2180
urine osmolality and, 579
Fusidic acid, 914t
G
Gabapentin (Neurontin), 1180, 1181t, 1187t, 1189, 1194t, 1195, 1224, 1242, 1271t, 1272, 1279t, 1281,
1845
androgen deprivation therapy, 2097
for diabetes, 1145
for PHN, 1654
for seizures, 1284t
for vasomotor symptoms, 1036t
Gabapentinoids, 1193
Gabitril (see Tiagabine)
Gadolinium-based contrast (GBC) agents, 643
Galantamine
for Alzheimer’s disease, 2239
for vascular dementia, 2242
Gallium nitrate, for hypercalcemia, 589t, 590
Gamma-glutamyl transferase (GGT), 1894
γ-Hydroxybutyric acid (GHB), 1882
Ganciclovir (Cytovene), 742, 743, 744, 1613, 1649t
adjunctive therapy, 1608t
adjusted dosage, 1610t
advantages, 1608t
adverse effects of, 1334t, 1608t, 1647t
for CMV disease, 1607
CrCl, 1610t
disadvantages, 1608t
dose-limiting toxicity, 1607
dosing of, 1337t
dosing regimens, 1608t
ganciclovir-induced bone marrow suppression, 1607
for herpes simplex keratitis, 1168
important drug interactions, 1608t
induction dose of, 1607
intraocular implants, 1608–1609, 1613
intravitreal administration, 1613
mode of administration, 1607
monitoring requirement, 1609t
normal dosage, 1610t
precautions and contraindications, 1609t
Ganciclovir-foscarnet combination, for CMV retinitis, 1612
Garamycin (see Gentamicin)
Gardasil, 1359
GBC agents (see Gadolinium-based contrast (GBC) agents)
Gefitinib, 470t
Gelclair, 1975
Gemcitabine (Gemzar), 469t, 1978t, 1994t
for NSCLC, 2062t, 2064t
Gemfibrozil, 120t, 123, 124, 124t, 125, 606
Gemifloxacin (Factive), 1326t
Gemzar (see Gemcitabine)
Genistein, 1030
Gentamicin (Garamycin), 658, 659, 665, 669, 670–671, 822, 1165, 1325t, 1724
adverse effects of, 1332t
for bacterial endocarditis, 644, 645
for CAPD-associated peritonitis, 1476t
for chorioamnionitis, 996
for CNS infections, 1373t
p. 2302
p. 2303
for cystic fibrosis, 461t
dosing of, 1337t
for enterococcal endocarditis, 1397t, 1398
for gram-negative aerobes, 1327t
for NEC, 2183
nephrotoxic antibiotic, 644
for UTI, 1497t
vancomycin and, 1398
Gentian violet, 1626
Geodon (see Ziprasidone)
GGT (see Gamma-glutamyl transferase (GGT))
GHB (see γ-Hydroxybutyric acid (GHB))
Ginger, for NVP, 976t
Ginseng, 942t
Glargine, 980
Glatiramer acetate, 1222
adverse effects of, 1225
patient characteristics and other factors associated with reduced adherence to, 1226t
patient counseling points for, 1226t
Gleevec (see Imatinib)
Glimepiride, 127, 1122, 1140
for type 2 diabetes, 1122, 1136, 1137
Glipizide, 127
for type 2 diabetes, 1122
GLP (see Glucagon-like peptide-1 agonists (GLP))
Glucagon, 689t, 1140
for hypoglycemia, 1107
Glucagon-like peptide-1 agonists (GLP)
adverse effects of, 1126–1127
contraindications and precautions of, 1127
dosage and clinical use, 1127
drug interactions, 1127
efficacy of, 1127
mechanism of action, 1126
pharmacokinetics of, 1126
Glucarpidase, 1992
Glucocorticoids
antenatal administration, 994
for fetal lung maturation, 986
for NVP, 976t
for prostate cancer, 2094
Glucomannan, 765t
Glucosamine, 867
Glucose, 585–586
administration, 611
for hyperkalemia, 587t
hypokalemia and, 583t
tablets for hypoglycemia, 1107
Glucosidase inhibitors
adverse effects of, 1125
contraindications and precautions of, 1125
dosage and clinical use, 1126
drug interactions, 1125
efficacy of, 1126
mechanism of action, 1125
pharmacokinetics of, 1125
Glutamatem, 1224
Glutamine, 1986
Glutathione, 1986
Glyburide, 127, 678, 981, 1001
for type 2 diabetes, 1122
Glycerol, 792
Glycoprotein IIb/IIIa inhibitors, 1312
, for ACS, 241t, 256t
Glycopyrrolate
for COPD, 420t
for end-of-life care, 89
Glycyrrhetinic acid, 1975
Gold, 881, 883
Golimumab, 881, 882, 895, 896t
for PsA, 842–843
Gonadotropin-releasing hormone (GnRH) agonists, 1019–1020, 1020t
adverse effects, 1022
for depressive disorders, 1815t
for endometriosis, 1021–1022
Gonadotropin-releasing hormone (GnRH) analogs, for IVF, 962–964
Gonadotropin-releasing hormone (GnRH) therapy, for prostate cancer, 2084, 2090
Goserelin (Zoladex), 1020t, 1021
Granisetron (Kytril), 472t
for PONV, 478t
Grastek, for allergic rhinitis, 435t
Grazoprevir, for HAV, 1688, 1689
Green tea, 765t
Griseofulvin, 942, 942t, 1624, 1624t, 1627
risk factor C, 1637
Guanabenz, 159, 2261t
Guanfacine, 159, 2261t
for ADHD, 1868t, 1870
Guarana, 765t
H
H2RAs (see Histamine-2 receptor antagonists (H2RAs))
HAART (see Highly active antiretroviral therapy (HAART))
Haemophilus influenzae type b (Hib), 1355, 1357–1358
Halcion (see Triazolam)
Haldol (see Haloperidol)
Halfan (see Halofantrine)
Halofantrine (Halfan), 1695
Haloperidol (Haldol), 472t, 1215, 1267, 1789t, 1797t, 1799t
drug interaction with smoking, 1906t
for end-of-life care, 89
for hyperprolactinemia, 1803
for OCD, 1760
for schizophrenia, 1793, 1793t
Haloperidol decanoate, 1795t
HAT (see Heparin-associated thrombocytopenia (HAT))
Havrix, 1357
Hawthorn, 304
HCTZ (see Hydrochlorothiazide (HCTZ))
Heat therapy, 1627
Helioplex, 852
Hemoglobin F, for vaso-occlusive complications, 1940
Heparin, 177t, 662, 1311–1312
for ACS, 241t
adverse effects of, 185–186
and breast milk, 1001
doses of, 183–184
dosing nomogram, 184, 185t
drug interaction with smoking, 1906t
duration of therapy, 184–185
hemorrhage from, 186
hypersensitivity reactions of, 186–187
induced thrombocytopenia, 186t
osteoporosis from, 186
protamine and, 187
reversal of effect, 187
therapeutic monitoring, 184
thrombocytopenia from, 185–186
for thrombosis, 176–177
Heparin-associated thrombocytopenia (HAT), 185
Heparinoids, 1311–1312
HepatAmine, 794t
HepAtasol, 794t
Hepatitis A (Hep A) vaccines, 1357 (see also Vaccination)
Hepatitis B immunoglobulin (HBIG), 1355
Hepatitis B (HepB) vaccine, 1355–1356 (see also Vaccination)
Hepatotoxicity
from isoniazid, 1435–1436
isoniazid–rifampin and, 1437
rifampin and, 1437
Herceptin (see Trastuzumab)
Heroin
and lactation, 1003t
for opioid withdrawalsyndrome, 1878
Hib polysaccharide conjugate vaccines (HbCV), 1358
HiDAC (see High-dose cytarabine (HiDAC))
High-dose cytarabine (HiDAC), 2025, 2028
Highly active antiretroviral therapy (HAART), 1596, 1597
and cryptococcosis, 1614
discontinuation of, 1598–1599
impact on CD4+lymphocytes, 1598
impact on opportunistic infections (OIs), 1598
and prevalence of CMV, 1607
Histamine-2 receptor antagonists (H2RAs), 484, 493t, 1215, 1216t
concomitant administration of, 484
for GER, 2162–2163, 2163t
for GERD, 508
and PPI, in combination, 508
in preventing SRMB, 514
for upper GI bleeding, 512–513
HIV protease inhibitors, 120t
H
M
GC
o
A
r
e
d
u
c
t
a
s
e
i
n
h
i
b
i
t
o
r
s
,
9
1
4
t
H
o
m
o
s
a
l
a
t
e
,
8
4
9
t
,
8
5
2
H
o
m
o
v
a
n
i
l
l
i
c
a
c
i
d
(
H
VA
)
,
2
0
0
3
H
o
o
d
i
a
,
7
6
5
t
H
S
(
s
e
e
H
yp
e
rt
o
n
i
c
S
a
l
i
n
e
(
H
S
)
)
H
u
m
a
l
o
g
(
s
e
e
I
n
s
u
l
i
n
l
i
s
p
r
o
)
H
u
m
a
n
e
ryt
h
r
o
p
o
i
e
t
i
n
-
e
p
o
e
t
i
n
a
l
fa
,
6
1
4
–
6
1
5
H
u
m
u
l
i
n
N
,
1
0
8
7
p. 2
3
0
3
p. 2
3
0
4
H
VA
(
s
e
e
H
o
m
o
v
a
n
i
l
l
i
c
a
c
i
d
(
H
VA
)
)
H
y
a
l
u
r
o
n
i
c
a
c
i
d
,
1
9
7
5
H
y
a
l
u
r
o
n
i
d
a
s
e
,
1
9
8
1
t
H
y
c
a
m
t
i
n
(
s
e
e
T
o
p
o
t
e
c
a
n
)
H
y
d
r
a
l
azi
n
e
,
1
5
7
t
,
2
9
4
,
3
3
5
t
,
3
4
4
,
9
8
6
,
9
8
7
,
2
2
6
1
t
c
o
ntr
a
in
dic
a
t
io
n
s
o
f,
3
4
4
do
s
e
s
o
f,
3
4
4
fo
r
H
F
,
2
7
1
fo
r
hyp
e
r
t
e
n
s
io
n
,
1
6
0
in
p
a
t
ie
nt
s
w
ith
C
K
D
,
6
1
7
H
y
d
r
o
c
h
l
o
ri
c
a
c
i
d
(
H
C
l
)
,
5
6
4
H
y
d
r
o
c
h
l
o
r
o
t
h
i
azi
d
e
(
H
C
T
Z)
,
2
2
2
3
fo
r
a
g
it
a
t
e
d
b
e
h
a
v
io
r
s
,
2
2
4
3
a
n
d
b
r
e
a
s
t
milk
,
1
0
0
2
fo
r
hyp
e
r
t
e
n
s
io
n
,
1
4
8
,
2
2
4–
2
2
5
H
y
d
r
o
c
o
d
o
n
e
,
1
1
8
7
t
H
y
d
r
o
c
o
rt
i
s
o
n
e
fo
r
B
P
D
,
2
1
7
5
fo
r
p
r
o
s
t
a
t
e
c
a
n
c
e
r
,
2
0
9
4
v
a
le
r
a
t
e
,
8
1
6
H
y
d
r
o
c
o
rt
i
s
o
n
e
c
r
e
a
m
(
Xe
r
e
s
e
)
,
1
6
5
0
H
y
d
r
o
m
o
rp
h
o
n
e
,
1
1
7
8
,
1
1
7
9
,
1
1
8
7
t
,
1
1
9
9
do
s
a
g
e
o
f,
1
1
9
9
t
H
y
d
r
o
m
o
rp
h
o
n
e
(
D
i
l
a
u
d
i
d
)
,
6
7
7
H
y
d
r
o
x
o
c
o
b
a
l
a
m
i
n
,
3
4
2
H
y
d
r
o
x
y
c
h
l
o
r
o
q
u
i
n
e
,
7
0
7
–
7
0
8
,
7
1
2
t
,
7
1
3
t
,
8
8
1
,
8
8
4
,
8
9
1
–
8
9
2
,
8
9
4
p
s
o
r
ia
s
is
a
n
d
,
8
3
4
H
y
d
r
o
x
y
c
i
t
ri
c
a
c
i
d
,
7
6
5
t
H
y
d
r
o
x
yp
y
ri
d
o
n
e
,
1
6
2
6
H
y
d
r
o
x
y
u
r
e
a
,
4
7
0
t
,
1
9
7
8
,
1
9
7
8
t
,
2
0
2
7
fo
r
v
a
s
o
-
o
c
c
lu
s
iv
e
c
o
mp
lic
a
t
io
n
s
,
1
9
4
0
H
y
d
r
o
x
yzi
n
e
(
Vi
s
t
a
ri
l
)
fo
r
N
V
P
,
9
7
5
,
9
7
6
t
fo
r
p
rur
itu
s
,
8
1
9
H
y
o
s
c
y
a
m
i
n
e
(
s
e
e
a
l
s
o
A
n
t
i
s
p
a
s
m
o
d
i
c
s
)
fo
r
e
n
d
-
o
flife
c
a
r
e
,
8
9
H
yp
e
rt
o
n
i
c
S
a
l
i
n
e
(
H
S
)
,
3
5
5
,
4
5
9
fo
r
a
ir
w
a
y
c
le
a
r
a
n
c
e
tr
e
a
tme
nt
,
4
5
9
H
yp
n
o
t
i
c
s
,
1
7
6
4
,
1
7
6
8
a
n
d
s
le
e
p
,
1
7
7
4
H
yp
o
g
l
y
c
e
m
i
c
s
,
9
8
0
–
9
8
1
I
Ibandronate, 2277, 2277t, 2278
Ibrutinib, 470t
Ibuprofen, 460, 870, 870t, 887, 888t, 1187t
for dysmenorrhea, 1015
for HF, 275
and hyperkalemia, 585
for PDA, 2179
Ibutilide, for AF, 315
ICE, for aggressive lymphomas, 2041–2042
Ice therapy, 915
Icodextrin, 661
Idamycin (see Idarubicin)
Idarubicin (Idamycin), 469t, 1979t, 1988
for AML, 2025
Idarucizumab, 1316
Idelalisib, 470t, 914t
IDV (see Indinavir (IDV))
Ifex (see Ifosfamide)
IFNs (see Interferons (IFNs))
Ifosfamide, 469t, 1991, 1991t
and cranial neuropathies, 1987
encephalopathic toxicity of, 1985
and encephalopathy, 1986
neurotoxicity of, 1985t
for osteosarcoma, 2008
for rhabdomyosarcoma, 2010, 2011
Iloperidone (Fanapt), 1797t, 1799t
for hyperprolactinemia, 1803
for schizophrenia, 1790, 1791t
Iloprost, 924
Imatinib (Gleevec), 128, 470t, 1977, 1990, 1996, 1996t, 2031
drug interactions with, 48–49
131
I-MIBG, 2006
Imidazoles, 1625
Imipenem-cilastatin (Primaxin), 1326t
for aerobic gram-positive cocci, 1326t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
for cystic fibrosis, 461t
dosing of, 1337t
for febrile neutropenia, 1561
for skin and soft tissue infections, 1550
for UTI, 1497t
Imipenem/meropenem/doripenem, for gram-negative aerobes, 1327t
Imipramine
for depressive disorders, 1819t, 1821t
hydrochloride, 2252
for panic disorder, 1748
Imiquimod, 1651
for genital warts, 1532
Immunoglobulin, 742
G antibodies, 455–456
for HAV, 1666
for HBV, 1675, 1680–1681
for Rh-associated HDN, 998–999
Immunoglobulin G (IVIG), for skin and soft tissue infections, 1551
Immunomodulators
for PsA, 842
for psoriasis, 836t
Immunosuppressants and lactation, 1003t
Immunotherapy
for allergic rhinitis, 434–435
for rhinitis, 444–445
Inactivated polio vaccine (IPV), 1355, 1358
Inapsine (see Droperidol)
Incretin, for type 2 diabetes, 1126
Indacaterol, for COPD, 420t, 421, 422
Indinavir (IDV), 128, 942t, 1579t
Indomethacin, 870t, 887, 888t, 993, 1187t
for hypercalcemia, 589t, 591
for PDA, 2179, 2180
Induction therapy, for AML, 2026–2028
Infanrix, 1357
Infliximab, 881, 882, 895, 896t
for IBD patients, 524
for inflammatory bowel disease, 522t
for PsA, 842–843
for treatment of CD, 531
for UC, 527–528
Influenza vaccine, 1360–1361
Inhaled β2
-agonists, 459
Inositol, 1849
Insulin
administration of, 611
adverse effects of, 1105–1108
clinical use of, 1091–1101
delivery of, 1091, 1093–1094
for diabetes, 167
for DKA management, 1111
endogenous, 1084
evaluation of, 1097–1098
for hyperkalemia, 587t
intensive vs. conventional glycemic control with, 1104t
measuring and injecting, 1094–1095, 1094f
mixing, 1099
monotherapy with type 2 diabetes, 1138–1139
pharmacodynamics of, 1084–1087, 1085t
pharmacokinetics of, 1084
premixed, 1139
stability, 1099
therapy, 980
therapy, basal, 1139
Insulin aspart (NovoLog), 1086
Insulin degludec (Tresiba), 1087
Insulin detemir (Levemir), 980, 1087
Insulin glargine (Lantus), 1087
Insulin glulisine (Apidra), 980, 1086
Insulin lispro (Humalog), 1085–1086
Interferon alpha, 469t
I
n
t
e
r
fe
r
o
n
s
(
I
F
N
s
)
fo
r
d
e
p
r
e
s
s
iv
e
dis
o
r
d
e
r
s
,
1
8
1
5
t
fo
r
H
B
V
,
1
6
7
7
fo
r
S
A
R
S
,
1
6
6
0
I
n
t
e
rl
e
u
k
i
n
-
2
,
fo
r
d
e
p
r
e
s
s
i
v
e
d
i
s
o
r
d
e
r
s
,
1
8
1
5
t
I
n
t
e
r
m
e
zz
o
,
fo
r
t
r
e
a
t
m
e
n
t
o
f
i
n
s
o
m
n
i
a
,
1
7
6
7
t
I
n
t
r
a
m
u
s
c
u
l
a
r
m
e
t
h
yl
p
r
e
d
n
i
s
o
l
o
n
e
,
9
2
5
I
n
t
r
a
n
a
s
a
l
c
o
rt
i
c
o
s
t
e
r
o
i
d
s
fo
r
a
lle
r
g
ic
r
h
init
is
,
4
3
3
fo
r
r
h
init
is
,
4
3
9
–
4
4
2
,
4
4
1
t
I
n
t
r
a
o
c
u
l
a
r
g
a
n
c
i
c
l
o
v
i
r
i
m
p
l
a
n
t
s
,
1
6
0
8
–
1
6
0
9
,
1
6
1
3
I
n
t
r
av
e
n
o
u
s
(
I
V)
a
l
b
u
m
i
n
i
n
fu
s
i
o
n
s
,
5
4
5
I
n
t
r
av
e
n
o
u
s
k
e
t
o
r
o
l
a
c
,
1
1
8
0
I
n
t
r
av
e
n
o
u
s
l
i
d
o
c
a
i
n
e
,
1
1
8
2
I
n
t
r
av
e
n
o
u
s
n
i
t
r
o
g
l
y
c
e
ri
n
,
2
9
7
I
n
v
a
n
z
(
s
e
e
E
rt
a
p
e
n
e
m
)
I
n
v
e
g
a
(
s
e
e
P
a
l
i
p
e
ri
d
o
n
e
)
I
o
d
i
n
e
s
,
1
6
2
6
a
n
d
p
r
e
gn
a
n
c
y
,
9
6
8
I
o
d
o
q
u
i
n
o
l
,
1
7
0
6
fo
r
a
me
b
ic
id
e
s
,
1
7
0
3
t
fo
r
a
me
b
ic
liv
e
r
a
b
s
c
e
s
s
,
1
7
0
3
t
fo
r
g
a
s
tr
o
int
e
s
t
in
a
l
dis
e
a
s
e
,
1
7
0
3
t
I
o
p
i
d
i
n
e
(
s
e
e
A
p
r
a
c
l
o
n
i
d
i
n
e
)
I
p
i
l
i
m
u
m
a
b
,
4
6
9
t
,
1
9
7
6
I
P
L
E
D
GE
p
r
o
g
r
a
m
,
8
3
0
I
p
r
a
t
r
o
p
i
u
m
b
r
o
m
i
d
e
(
A
t
r
o
v
e
n
t
)
,
4
4
0
t
fo
r
a
lle
r
g
ic
r
h
init
is
,
4
3
4
fo
r
B
P
D
,
2
1
7
5
fo
r
C
O
P
D
,
4
2
0
t
,
4
2
1
I
P
V
(
s
e
e
I
n
a
c
t
i
v
a
t
e
d
p
o
l
i
o
v
a
c
c
i
n
e
(
I
P
V)
)
I
rb
e
s
a
rt
a
n
,
fo
r
h
yp
e
rt
e
n
s
i
o
n
,
1
5
4
t
p. 2
3
0
4
p. 2
3
0
5
I
ri
n
o
t
e
c
a
n
,
4
6
9
t
,
1
9
7
6
,
1
9
9
6
fo
r
a
dv
e
r
s
e
e
ffe
c
t
s
,
2
0
8
0
fo
r
c
o
lo
n
c
a
n
c
e
r
,
2
0
7
3
drug
int
e
r
a
c
t
io
n
w
ith
s
mo
kin
g
,
1
9
0
6
t
fo
r
r
h
a
b
do
my
o
s
a
r
c
o
ma
,
2
0
1
0
,
2
0
1
1
fo
r
S
C
L
C
,
2
0
6
8
t
I
r
o
nfor
a
n
e
mia
,
1
9
3
0
a
n
d
dy
s
p
e
p
s
ia
,
4
8
7
GE
R
D
a
n
d
,
5
0
3
t
in
g
e
s
t
io
n
o
f,
a
s
s
e
s
s
me
nt
o
f,
7
0–
7
4
a
n
d
p
r
e
gn
a
n
c
y
,
9
6
8
–
9
6
9
I
r
o
n
d
e
x
t
r
a
n
,
6
1
4
fo
r
a
n
e
mia
,
1
9
3
1
,
1
9
3
2
,
1
9
3
3
inj
e
c
t
io
n
,
6
9
6
I
r
o
n
s
u
c
r
o
s
e
,
6
1
4
fo
r
a
n
e
mia
,
1
9
3
1
,
1
9
3
2
,
1
9
3
3
I
s
av
u
c
o
n
az
o
l
e
,
1
6
2
4
t
adverse effects of, 1334t
Isoflavone, 1030
Isoniazid, 484, 942
and allergic reactions, 1436
dosing of, 1337t
drug interactions with, 1436
hepatotoxicity from, 1435–1436
for HIV-infected and TB, 1616
and peripheral neuropathy, 1436
for tuberculosis, 53, 54t, 1429t, 1433
Isoproterenol, 363t
GERD and, 503t
for postoperative cardiac failure, 363t
Isopto Carpine (see Pilocarpine)
Isosorbide, 1158
Isosorbide-5-mononitrate, 550
Isosorbide dinitrate (BiDil), 221, 294, 295
Isotretinoin, 942t
for acne, 830–831
teratogenic effects, 973t
Isradipine, for chronic stable angina pectoris, 214
Itraconazole, 120t, 128, 484, 942t, 1615, 1624t, 1625, 1626t, 1627–1628
antifungal agents, 41
adverse effects of, 1334t
for chronic pulmonary blastomycosis, 1637
CNS penetration of, 1640
dosing, 1628
for S. schenckii, 1627
Ivabradine (Corlanor), 272
Ivacaftor (Kalydeco), 60
CFTR potentiator, 451–452
IV antipseudomonal antibiotics, 463
IV colistin, 460
IV diltiazem, for AF, 345
Ivermectin, 1711
for lice, 1704t
No comments:
Post a Comment
اكتب تعليق حول الموضوع